The only Global Contract Development and Manufacturing Facilities Database subscription that actively tracks over 400+ dedicated CDMO facilities providing development and manufacturing services for biopharmaceuticals.
Hundreds of facilities manufacturing clinical and commercial scale biologics, account for $16.89 billion in services sales in 2023, growing at 17% annually.
Based on 30 years of evaluating and benchmarking the biopharmaceutical and life sciences industry, this database is updated continually and includes comprehensive information and insights.
"Top300 Bio CDMO Facility Index" ranks each 'dedicated' CDMO facility and provides regional quantitative analysis of biomanufacturing regions and clusters.
Total bioreactor liter capacity
CDMO/CMO service expertise
Future Biomanufacturing capacity coming online
Number of commercial and clinical biological products manufactured
Revenue estimates
Strengths and Challenges
Technologies and expertise, and much more
USES FOR THE TOP300BIOCDMO.COM
Identify your ideal CDMO or partners
Identify specialized expertise such as cell or gene therapy, pDNA, mRNA
Early-stage companies: sponsors can identify potential manufacturing partners